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Abstract: This study was an attempt to determine the effect of a selected anthracycline derivative, WP903, on apoptotic
processes in human melanoma cells depending on intracellular concentrations of the compound, and to evaluate the significance
of apoptosis induction for the cytotoxic effect of anthracycline antibiotics. It was found that the WP903, contrary to ADR
(adriamycin) is a strong inducer of apoptotic processes in ME18 human melanoma cells regardless of their susceptibility to
adriamycin and WP903. The cells were treated for 24 h with ADR (1 and 5 µg/ml) or WP903 (0.2 and 2 µg/ml). Apoptosis
was detected with the use of annexin V-FITC and PI (propidium iodide) and with TUNEL assay. WP903 used at 0.2 µg/ml
induced early apoptosis in 23% of ME18 cells and in 60% of ME18/R cells; at 2 µg/ml in 70% of each of cell line tested.
Significant late apoptotic effect was observed in ME18 cells. In contrast, ADR was found to be a weak inducer of apoptotic
events. The results suggest that apoptosis is not a mechanism directly related to the cytotoxic effect of anthracycline antibiotics.
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Introduction
The use of anthracyclines as antitumor drugs dates back
to the seventies. In this group of chemotherapeutics,
ADR remains constantly the compound that has the
widest spectrum of activity. It is used in the treatment of
solid tumours, including tumours of the breast, bile
ducts, uterus, oesophagus, liver, osteosarcomas and soft
tissue sarcomas, as well as acute myeloblastic and lym-
phoblastic leukaemia [7].
The cytotoxic effect of anthracycline antibiotics is
multidirectional. One of the mechanisms consists in
blocking the cleavable complex of DNA and topoisome-
rase II supervising the superhelicity of DNA strands. A
positive correlation was found between the cytotoxic
effect and topoisomerase II-mediated DNA breaks [2,
7]. The other mechanisms of ADR effect on the cell
include formation of adducts (leading, among others, to
the formation of crosslinks); intercalation of the ADR
molecule between the DNA strands and induction of
micronuclei [3, 4, 6]. ADR generates numerous damages
in the DNA, and also in cell membrane structure or cell
enzymatic systems, due to the free radical mechanism
resulting from metabolic transformation of the drug to a
transient radical from [6, 8, 14]. A very important target
site for anthracycline antibiotics are cell proliferation
control systems including the apoptotic process which
is emphasized in the recent years. Ling et al. [11] suggest
that induction of apoptosis is the primary mechanism of
cytotoxic activity of anthracyclines used in the concen-
tration range up to 10 µM. The effect of this group of
compounds as apoptosis stimulators on tumour cells is
indirect, i.e. they influence the activity of specific genes
and their products - regulatory proteins.
Because of a serious problem in chemotherapy, and
in particular anthracycline therapy, consisting in the
phenomenon of multidrug resistance and high cardio-
toxicity, new anthracycline derivatives having better
therapeutic index are being sought. The search is aimed
at selecting derivatives with unchanged or increased
antitumor activity, it should lead to cardiotoxic effect
reduction and to an increase in the active molecule
affinity to the target site which is related to the increase
in its lipophilic properties [1, 15].
As a part of cooperation with the group of Prof.
Waldemar Priebe from the M.D. Anderson Cancer Cen-
ter in Houston (USA), screening studies of a number of
new anthracycline compounds in the aspect of their
cytotoxic effect on the cells and intracellular transport
in comparison with known and used anthracycline anti-
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biotic, ADR, were performed at the Department of Bio-
chemistry and Biopharmaceuticals of the NIPH. The
studies have shown that the highest cytotoxic activity
(i.e. relatively low values of IC50 and RF = resistance
factor) can be attributed to the derivative known as
WP903. It was also found that this compound enters the
cells to the highest degree among the tested substances.
The purpose of this study was to evaluate the effect
of a new synthesized anthracycline derivative WP903
on apoptosis induction in human melanoma cells, ME18,
and an experimentally obtained ADR-resistant subline,
ME18/R. The observed effect of apoptosis induction by
WP903 was discussed in relation to the effects obtained
for ADR.
This study was an attempt to determine the effect of
the derivative on the induction of apoptotic processes
depending on the concentrations used and the signific-
ance of apoptosis induction on the cytotoxic effect of
anthracycline antibiotics.
Materials and methods
Reagents. ADR (adriamycin) was purchased from Fluka, Germany;
antibiotics and antimycotics (penicillin 10 000 u/ml; streptomycin
10 mg/ml; amphotericin B 25 µg/ml) and PBS were obtained from
IITD, Wrocław, Poland; apoptosis detection kit Annexin V came
from Caltag Laboratories, USA; APO-BRDUTM kit for TUNEL
assay was purchased from BD Pharmingen, USA; new synthesized
anthracycline derivative WP903 was received from MD Anderson
Cancer Center, Houston, USA.
Cell cultures. ME18-human melanoma cell line was obtained from
the Centre of Oncology in Warsaw; ME18/R - human melanoma
subline resistant to ADR was obtained experimentally in our labor-
atory (for this subline, resistance to WP903 was also shown).
Annexin assay by flow cytometry. 24-h cell cultures were exposed
to ADR at concentrations of 1 and 5 µg/ml or to the WP903 derivative
at concentrations of 0.2 and 2 µg/ml for subsequent 24 h. Afterwards,
the cultures were rinsed twice using cold PBS, trypsinized and, after
centrifugation, resuspended in a buffer (10 mM Hepes/NaOH,
pH=7.4; 140 mM NaCl; 2.5 mM CaCl2). The suspension density was
approximately 106 cells/ml. Each cytometric tube was filled with 100
µl of the cell suspension; annexin V-FITC and PI were added to each
tube according to Annexin V kit procedure. After gentle shaking
using "vortex", the tubes were incubated at room temperature in
darkness for 15 min. The buffer (as above) was added and the samples
were measured within 1 h using FACS Vantage flow cytometer of
Becton Dickinson.
TUNEL assay by flow cytometry. Drug treatment and time expo-
sure of cell cultures were as above. The cells, harvested in 1% (w/v)
paraformaldehyde in PBS (pH=7.4), were fixed with use of 70%
(v/v) ice cold ethanol according to the APO-BRDUTM kit procedure
and stored at -20˚C until use. To follow TUNEL assay, the ethanol
was removed by aspiration and the cells were washed twice with
buffer containing 0.05% sodium azide. Then, the cell pellets were
treated with DNA labeling solution (constisting of TdT enzyme and
Br-dUTP). After 60 min incubation, the labeled cells were rinsed
twice with buffer containing 0.05% sodium azide and resuspended
in FITC-labeled anti-BrdU solution. Flow cytometry analysis of the
cells (as above) was performed after 30 min storage in the dark at
room temperature.
The concentrations of both compounds used in the experiment,
i.e. 0.2 and 2 µg/ml of WP903 or 1 and 5 g/ml of ADR, represented
values that were respectively lower or higher than the IC50 values
determined for susceptible cells. These values were obtained in
screening studies performed at our department [9]. The selection of
concentrations was aimed at possible confirmation of greater effi-
cacy of the derivative tested compared to ADR.
Statistical analysis. The statistical evaluation of the results was
performed using Student’s t-test, and C-Cochran and Cox test for
unrelated samples.
Results
The results, presented in Table 1, were compared in the
following system: lower and higher doses of WP903 (0.2
and 2 µg/ml) and lower and higher doses of ADR (1 and
5 µg/ml). As shown in Table 1, the WP903 derivative
induced apoptotic events in human melanoma cells,
regardless of the degree of sensibility to ADR and
WP903, at concentrations several times lower compared
to ADR concentrations.
In susceptible cells, ME18, the WP903 derivative
used at a dose of 0.2 µg/ml had an apoptotic effect in
more than 20% of cells, and at a dose of 2 µg/ml, approx.
70% of the cultured cells were in the early apoptosis
phase (Fig. 1). Significant late apoptotic effects, ob-
served in these experiments with use of annexin V-





Living cells Cells in early apoptosis Cells in late apoptosis and necrosis
ME18 ME18/R ME18 ME18/R ME18 ME18/R
– – 87.5 ± 1.5 73.2 ± 0.9 <1 <1 12.0 ± 1.0 25.3 ± 0.7
1 – 59.0 ± 7.9 65.0 ± 5.1 13.0 ± 3.5 <1** 28.7 ± 4.3 33.0 ± 6.0
5 – 33.7 ± 2.9 65.3 ± 2.2 10.3 ± 3.7*  2.7 ± 1.2*** 56.3 ± 6.4 31.2 ± 1.5
– 0.2 42.7 ± 6.9  9.0 ± 1.2 22.7 ± 9.0 59.7 ± 3.8** 34.3 ± 3.2 31.0 ± 2.3
– 2 <1 <1 69.3 ± 0.7* 71.0 ± 2.1*** 30.0 ± 1.0 26.3 ± 1.5
24-h cell cultures were exposed to WP903 (0.2 and 2 µg/ml) or ADR (1 and 5 µg/ml) for the next 24 h. Cells kept in drug-free MEM
were controls. After 24 h, the cells were treated with annexin V-FITC and PI (as described in Materials and methods). The results,
presented as percent of cells ± SEM are the means of at least three independent experiments. *p=0.004,  **p=0 .0042, ***p<0.0001 
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FITC, were confirmed by TUNEL assay (Fig. 3). ADR
at a dose of 5 µg/ml had a significantly lower apoptotic
effect (approx. 10%) compared to the WP903 derivative;
the dose of 1 µg/ml of ADR had no apoptotic effect at
all. In the case of resistant cells, ME18/R, the WP903
compound caused early apoptotic changes in approx.
60% of cells even at a dose of 0.2 µg/ml. At the higher
dose, 2 µg/ml, this effect was slightly increased (to
approx. 70%, Fig. 2). In these cells, the early phase of
Fig. 1. Exemplary cytograms of ME18 cells stained with annexin
V-FITC and PI; quadrants present as follows: LL-viable cells; LR-
cells in early apoptosis; UR-cells in late apoptosis; UL-cells in
necrosis. (A) untreated cells; (B) ME18 cells treated for 24 hrs with
2 µg/ml of WP903. X axis - fluorescence intensity of conjugates:
cells-annexin V-FITC; Y axis - fluorescence intensity of conjugates:
cells-PI.
Fig. 2. Exemplary cytograms of ME18/R cells stained with annexin
V-FITC and PI; quadrants present as follows: LL-viable cells; LR-cells
in early apoptosis; UR-cells in late apoptosis; UL-cells in necrosis. (A)
untreated cells; (B) ME18/R cells treated for 24 h with 2 µg/ml of
WP903. X axis - fluorescence intensity of conjugates: cells-annexin
V-FITC; Y axis - fluorescence intensity of conjugates: cells-PI.
Fig. 3. Histograms of ME18 cells fixed and incubated with Br-dUTP
in the presence of TdT enzyme. Br-dUTP was detected with a
fluorescein labeled anti-BrdU mAb; the M1 and M2 gates demarcate
non-apoptotic and late apoptotic populations, respectively. (A) un-
treated cells; (B) ME18 cells treated for 24 h with 0.2 µg/ml of
WP903; (C) ME18 cells treated for 24 h with 2 µg/ml of WP903. X
axis - fluorescence intensity of BrdU-fluorescein; Y axis - relative
cell number.
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apoptosis was mainly observed. DNA fragmentation in
the treated cells was observed at the level noted in the
untreated cells. This observation was confirmed by
TUNEL assay (data not shown).
Compared to ADR, WP903 showed significantly
higher apoptosis induction ability in ME18/R cells, re-
gardless of the dose used, although 2 µg/ml of WP903
was not efficient for ME18/R cells to induce DNA
fragmentation.
Discussion
The techniques developed for identification of the apop-
tosis phenomenon in a given population of cells not only
allow to determine the type of cell death but also the
phase of biochemical events typical for apoptosis
through the detection of characteristic features of each
phase [5]. The apoptotic process detection using annexin
is based on the phenomenon of membrane phosphati-
dylserine translocation onto the cell membrane surface
as a result of early apoptotic changes. Annexin V is a
Ca2+-dependent protein, having high affinity for phos-
phatidylserine. The cells which stain only with annexin
V-FITC are in the early phase of apoptosis. Positive
staining with annexin V-FITC and PI (penetrating to
dead cells) theoretically means late apoptosis; staining
with PI only indicates cell necrosis.
The APO-BRDUTM kit is a color staining method for
labeling DNA breaks to detect late phase of apoptosis. The
enzyme deoxynucleotidyl transferase (TdT) catalyzes a
template-independent addition of bromolated deo-
xyuridine triphosphates (Br-dUTP) to the 3’-hydroxyl
(-OH) ends of double- and single-stranded DNA. After
Br-dUTP incorporation, DNA break sites are identified by
a FITC-labeled anti-BrdU monoclocal antibodies.
The results obtained in this study indicate that the
WP903 derivative, contrary to ADR, has a very strong
apoptotic effect in human melanoma cells (22% to 70%
of cells) even when used at a low dose of 0.2 µg/ml. At
the same time, this induction does not depend on the degree
of cell susceptibility to this derivative. It shows that apop-
tosis is not a mechanism of anthracycline antibiotic action
directly responsible for their cytotoxic activity.
This observation is consistent with the results ob-
tained earlier in our laboratory for ADR [10], as well as
partially consistent with the results obtained by other
authors. According to Gewirtz [7], anthracycline anti-
biotics induce apoptosis only in low doses (up to 0.5
µg/ml), which was also shown by others [13] but this
effect seems to have no significance for the cytotoxic
activity of the drugs of this group.
In this study, the dose-dependent effect of WP903 on
the occurrence of the apoptosis was especially observed
in susceptible ME18 cells. In resistant cells, ME18/R,
the concentration of 0.2 µg/ml was shown to be efficient
to have maximum effect in this experiment. The result-
ing percentage of cells in early apoptosis (approximately
60%) changed very little at higher concentration of the
compound. The lack of DNA fragmentation was noted
after exposure of the cells to 2 µg/ml of WP903.
These observations are consistent with the report of
Binaschi et al. [2] who found that there are so-called
threshold concentrations, specific for each compound,
that could trigger an early DNA degradation process.
The level of this concentration probably depends on the
degree of severity of DNA degradation that may occur
during cell incubation with the tested compound, and the
intensity of apoptotic effects depends on the type of
apoptosis inductor and the cell exposure time [2, 12].
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